For physicians
Stay current without searching the literature.
Every Monday, one email with the key new trials and reviews in the topics you choose.
Start freeFree until 31 December · No card required
See a weekly digest
An example from Cardiology. Yours is built from the topics you choose.
Papertis Weekly
Selected for you
Here are the top 3 this week.
Blinded withdrawal of randomized treatment with low-dose digoxin or placebo in heart failure: the DECISION trial.
Key finding
Following blinded digoxin withdrawal, the incidence rate of cardiovascular death or worsening heart failure events rose to 42.8 versus 5.9 events per 100 patient-years in the placebo withdrawal arm (RR 7.37; 95% CI 1.56–34.88; P = .012), accompanied by increases in heart rate and NT-proBNP and a reduction in systolic blood pressure.
Also in the full summary
Practice impact: Relates to situations where discontinuation of long-term digoxin is being considered in patients with heart failure and a reduced or mildly reduced ejection fraction on contemporary guideline-recommended therapy.
Targeted Assessment in High-Risk Patients With Diabetes to Identify Undiagnosed Heart Failure (TARTAN-HF).
Key finding
At 6 months, heart failure was diagnosed in 24.6% of participants in the natriuretic peptide-based screening group versus 1% in the usual care group (OR: 58; 95% CI: 14–236; P < 0.001), with most newly identified cases being heart failure with preserved ejection fraction (23%).
Read the full summary →Left Bundle-Branch Area Pacing vs Right Ventricular Pacing for Atrioventricular Block and Preserved Left Ventricular Function: The LEAP-Block Randomized Clinical Trial.
Key finding
In 482 randomized patients (mean age 67 years, 46% female), LBBAP reduced the 24-month composite primary endpoint of all-cause death, heart failure events, or upgrade to biventricular pacing compared with right ventricular pacing (2.4% vs 12.5%; absolute risk difference −10.1% [95% CI −16.8% to −3.4%]; HR 0.37 [95% CI 0.19–0.73]).
Read the full summary →See an exceptional finding
Exceptional finding
Papertis alert, in your topics
Blinatumomab for replacing chemotherapy in pediatric acute lymphoblastic leukemia
Key finding
At a median follow-up of 2.9 years, 4-year event-free survival was 83.0% with blinatumomab vs 70.3% with standard chemotherapy (HR 0.51); treatment-related infections 23.9% vs 69.4%, neurotoxic events 12.0% vs 3.2%.
Why it matters
A randomized trial on a high-stakes treatment decision in pediatric high-risk B-cell ALL, with efficacy and safety data against standard chemotherapy.
Practice-changing papers don't wait for Monday: we email you as soon as we find one in your topics.
We screen papers from 3,000+ journals, including
NEJMThe LancetJAMABMJ
Free until 31 December 2026
No card required. Paid plans start in 2027.
Essential
US$3.49/month
Stay current in your specialty.
- 3 topics of your choice
- The best papers in your topics, every Monday
- Ongoing clinical trials
Complete
US$6.99/month
Your whole field, at a glance.
- Unlimited topics
- Every new paper: the best in your digest, the rest in your dashboard
- Exceptional findings: an alert when a practice-changing paper appears in your topics
- Retraction alerts: if a paper you received is later retracted or corrected
- Ongoing clinical trials
Your first digest arrives in minutes.
Pick your topics. Then every Monday, the key new papers.
Start freeFree until 31 December · No card required